Table 2 Clinicopathological characteristics of 70 patients aged ≥ 85 years who underwent ESD for gastric cancer
Tumor type, n (%) | |
Initial lesion | 64 (91.4) |
Metachronous lesion | 6 (8.6) |
Tumor location, n (%) | |
Upper | 13 (18.6) |
Middle | 23 (32.9) |
Lower | 34 (48.6) |
Tumor size, mm, median (range, IQR) | 13.0 (4–95, 9.0) |
Macroscopic appearance, n (%) | |
Elevated | 40 (57.1) |
Depressed/flat | 30 (42.9) |
Histology, n (%) | |
Differentiated type | 69 (98.6) |
Undifferentiated type | 1 (1.4) |
Depth, n (%) | |
M/SM1 | 67 (95.7) |
SM2 | 3 (4.3) |
Lymphatic invasion, n (%) | 4 (5.7) |
Vascular invasion, n (%) | 0 (0) |
Ulcerative findings, n (%) | 7 (10.0) |
Curability n (%) | |
eCuraA | 58 (82.9) |
eCuraB | 4 (5.7) |
eCuraC-2 | 8 (11.4) |
Additional gastrectomy, n (%) | 0 (0) |
Procedure time, min, median (range, IQR) | 37.5 (6–415, 41) |
Postoperative bleeding, n (%) | 1 (1.4) |
Perforation, n (%) | 1 (1.4) |
Other metachronous cancers, n (%) | 0 (0) |
Death due to any causes, n (%) | 33 (47.1) |
Death due to gastric cancer, n (%) | 0 (0) |